CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia

Clinica Chimica Acta; International Journal of Clinical Chemistry
Maria A V WillrichRosario D C Hirata

Abstract

The cytochrome P450 isoenzyme 3A5 (CYP3A5) has an important role on biotransformation of xenobiotics. CYP3A5 SNPs have been associated with variations on enzyme activity that can modify the metabolism of several drugs. In order to evaluate the influence of CYP3A5 variants on response to lowering-cholesterol drugs, 139 individuals with hypercholesterolemia were selected. After a wash-out period of 4 weeks, individuals were treated with atorvastatin (10 mg/day/4 weeks). Genomic DNA was extracted by a salting-out procedure. CYP3A5*3C, CYP3A5*6 and CYP3A5*1D were analyzed by PCR-RFLP and DNA sequencing. >Frequencies of the CYP3A5*3C and CYP3A5*1D alleles were lower in individuals of African descent (*3C: 47.8% and *1D: 55.2%) than in non-Africans (*3C: 84.9% and *1D 84.8%, p<0.01). Non-Africans carrying *3A allele (*3C and *1D combined alleles) had lower total and LDL-cholesterol response to atorvastatin than non-*3A allele carriers (p<0.05). CYP3A5*3A allele is associated with reduced cholesterol-lowering response to atorvastatin in non-African individuals.

References

Mar 17, 2001·British Journal of Pharmacology·K BogmanJ Drewe
Dec 12, 2001·Pharmacogenetics·E HustertL Wojnowski
Mar 20, 2002·The American Journal of Cardiology·Evan A Stein
Oct 31, 2002·Advanced Drug Delivery Reviews·Jatinder K LambaKenneth E Thummel
May 16, 2003·Clinical Chemistry and Laboratory Medicine : CCLM·Gerd Schmitz, Wolfgang Drobnik
May 20, 2003·Journal of Applied Physiology·Raymond C GivensPaul B Watkins
Oct 9, 2003·Clinical Pharmacokinetics·Hans Lennernäs
Apr 23, 2004·Pharmacogenomics·Hong-Guang XieGrant R Wilkinson
Jun 17, 2004·Circulation·Stefano BellostaAlberto Corsini
Jun 17, 2004·JAMA : the Journal of the American Medical Association·Daniel I ChasmanPaul M Ridker
Jun 26, 2004·Current Opinion in Cardiology·Bela F Asztalos, UNKNOWN HDL Atherosclerosis Treatment Study
Jul 2, 2004·Therapeutic Drug Monitoring·Leszek Wojnowski
Jul 31, 2004·Pharmacogenetics·Kari T KivistöTimo Strandberg
Aug 18, 2004·Circulation·Carl J Vaughan, Antonio M Gotto
Nov 9, 2004·Atherosclerosis. Supplements·Michael S Brown, Joseph L Goldstein
Nov 16, 2004·The American Journal of Cardiology·Georges ChahoudJawahar L Mehta
Dec 15, 2004·Hypertension·Herbert HoMyron H Weinberger
Jan 22, 2005·Fundamental & Clinical Pharmacology·Michael Schachter
May 19, 2005·Pharmacogenetics and Genomics·Russell A WilkeJames K Burmester
Sep 3, 2005·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·A C RodriguesR D C Hirata
Nov 3, 2005·Nature Reviews. Drug Discovery·Russell A WilkeJason H Moore
Nov 29, 2005·Clinical Chemistry and Laboratory Medicine : CCLM·Simone C SorkinRosario D C Hirata
Dec 1, 2005·European Journal of Pharmacology·Gérard SiestSophie Visvikis-Siest
Oct 13, 2006·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Su-Jun LeeRon H N van Schaik
Oct 24, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Nina IsoherranenMary F Paine
Nov 6, 2007·Pharmacogenomics·Guilherme Suarez-KurtzCláudio Struchiner
Jan 1, 2008·Clinica Chimica Acta; International Journal of Clinical Chemistry·Fabiana D V GenvigirRosario D C Hirata
Dec 19, 2012·Clinica Chimica Acta; International Journal of Clinical Chemistry·A C RodriguesR D C Hirata

❮ Previous
Next ❯

Citations

Feb 1, 2012·Genetic Testing and Molecular Biomarkers·Vivian N SilbigerRosario D C Hirata
Mar 13, 2012·Pharmacogenetics and Genomics·Jatinder LambaRuss B Altman
Jan 15, 2013·Drug Metabolism and Drug Interactions·Joseph Paul KitzmillerWolfgang Sadee
Jun 18, 2009·Pharmacogenomics·Maria Alice Vieira WillrichRosario Dominguez Crespo Hirata
Feb 9, 2012·Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation·Marjan RahsazSeid Ali Malekhosseini
Dec 17, 2015·Pharmacogenomics·Maarten LeusinkAnke H Maitland-van der Zee
Aug 14, 2012·Journal of Clinical Pharmacy and Therapeutics·X-Y JiangM Lu
Jun 1, 2011·Annals of Medicine·Cesare R SirtoriReijo Laaksonen
Aug 15, 2015·Genetics and Molecular Biology·Genovefa KolovouVangelis G Manolopoulos
Dec 7, 2017·Pharmacogenomics·Maria Alice V WillrichLinnea M Baudhuin
Mar 12, 2015·The Cochrane Database of Systematic Reviews·Stephen P AdamsJames M Wright
Dec 15, 2010·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Simran D S MaggoDavid W J Clark
Mar 22, 2014·The Open Cardiovascular Medicine Journal·Genovefa KolovouVangelis G Manolopoulos
Aug 21, 2013·Expert Review of Cardiovascular Therapy·Miao Hu, Brian Tomlinson
Apr 20, 2014·Drug Metabolism and Drug Interactions·Alvaro CerdaRosario Dominguez Crespo Hirata
Apr 11, 2015·International Journal of Molecular Sciences·Jenny LagosLuis A Salazar
Aug 14, 2009·Expert Review of Cardiovascular Therapy·Bas J M PetersAnke-Hilse Maitland-van der Zee
Jan 21, 2014·Molecular Biology Reports·Fabiana B KohlrauschMara H Hutz
Apr 4, 2021·Journal of Personalized Medicine·Pablo ZubiaurFrancisco Abad-Santos
Aug 18, 2021·Pharmacological Reports : PR·Carolina Dagli-HernandezRosario Dominguez Crespo Hirata
Nov 26, 2009·Current Opinion in Lipidology

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Related Papers

Clinica Chimica Acta; International Journal of Clinical Chemistry
Alvaro CerdaRosario D C Hirata
Pharmacogenomics
Maria A V WillrichRosario D C Hirata
Clinica Chimica Acta; International Journal of Clinical Chemistry
Christina L AquilanteCourtney V Fletcher
© 2022 Meta ULC. All rights reserved